As trade tensions with the US intensify, Beijing is transforming its pharma and med tech sectors, which only a few years ago were viewed as a relatively open and investment-friendly, into a strategic arena for self-reliance and technological control. This shift is not just reactive, it is a deliberate move and one that may end up reshaping the rules of global healthcare investment.



